
Insightec raises $150M for incisionless surgery
Insightec, a company making an ultrasound device that can be used to treat essential tremor, raised $150 million. The company now has a post-money valuation of $1.3 billion.
Insightec, a company making an ultrasound device that can be used to treat essential tremor, raised $150 million. The company now has a post-money valuation of $1.3 billion.
Focused ultrasound, essentially concentrated sound waves, have been used in early-stage clinical trials to temporarily disrupt the blood-brain barrier, creating a window of time where a therapeutic treatment could be delivered in a targeted manner. The potential impact of this advancement is enormous.
The Israeli company's technology uses the power of focused ultrasound guided by MR imaging to target conditions like essential tremor, Parkinson's disease and neuropathic pain.
Healthcare practitioners will integrate new medtech tools into clinical practice and create more effective and safe procedures globally, but doing so successfully requires the medtech industry to address certain acute healthcare issues.
The ExAblate device's label, an ultrasound technology designed to treat uterine fibroids, has been adapted in order for it to be available to women who want to keep their uterus intact while still having the option to get pregnant.
While we all marveled over Medtronic’s latest DBS system, GE-held Insightec (based in Israel) has published results from a pilot study in the NEJM that may validate the Exablate Neuro, a device that combines focused ultrasound surgery with continuous MRI via a “helmet” transducer that shoots out ultrasound elements, stopping the tremors. It’s “noninvasive, incisionless […]
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.